PACIFIC RESEARCH NETWORK
3003 Fourth Avenue, San Diego, CA 92103 * (619) 294-4302 Ph. (619) 294-4867 Fax

THOMAS J. REILLY, M.D., MPH

EDUCATION

1993 MPH: San Diego State University, San Diego, California
1983 Post Graduate: Oakland Naval Hospital, Oakland, California
1982 Medical: Georgetown University School of Medicine, Washington, DC
1978 BS: Vanderbilt University, School of Engineering, Nashville, Tennessee

MEDICAL EXPERIENCE

2004 – Present Staff Physician, Pacific Research Network, San Diego, California
2010 - 2011 Chairman, iCOMPLYToday, San Diego, California
2009 - 2011 Alternate Board Member, Total IRB, Raleigh, North Carolina
2007 – Present Board Member, Aspire Institutional Review Board, San Diego, California
2005 – Present Community Member, Institutional Bio-safety Committee, Kaiser Permanente Southern California
1998 – Present Volunteer Preceptor, University of California San Diego School of Medicine San Diego, California
2004 – 2007 Chairman, Aspire Institutional Review Board, San Diego, California
2001 – 2004 Institutional Review Board Member, Vice Chair, Medical Consultant, Biomedical Research Institute of America, San Diego, California
1994 – 1995 Medical Officer, America's Cup Challenger Series
1991 – 1992 Medical Officer, America's Cup Challenger Series
1990 – 2000 Associate Medical Director, Occupational Medicine Chula Vista, Sharp-Rees Stealy Medical Group, San Diego, California
1988 – 1989 Staff Physician, Sharp-Rees Stealy Medical Group, San Diego, California
1986 - 1987 Officer in Charge, Flight Line Clinic, U.S. Navy, Moffett Field, California
1984 – 1987 Flight Surgeon, U.S. Navy
1986 – 1987 Regional Naval Medical Clinic Executive Policy Committee, U.S. Navy

1984 – 1985	Special Board of Flight Surgeons, U.S. Navy
1983 - 1984	Emergency Room Physician, Oakland Naval Hospital, Oakland, California

CERTIFICATION AND LICENSURE

Board Certification in Occupational and Environmental Medicine

LICENSURE: State of California
License Number: G 51288
Expiration Date: January 31, 2015

CLINICAL RESEARCH EXPERIENCE

1. A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Attenuate the Progression of Alzheimer's Disease. (00026)

2. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of XXXX in Patients with Mild-To-Moderate Dementia of the Alzheimer's Type. (202793)

3. A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety and Efficacy of XXXX 25 mg in Slowing the Progression of Alzheimer's Disease. (202531)

4. A Double-Blind, Phase II, Safety and Efficacy Evaluation of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203096PRN)

5. An Evaluation of the Long-Term Safety and Efficacy of XXXX in Patients with Moderate to Severe Dementia of the Alzheimer's Type. (202891)

6. A Long-Term Extension Study Evaluating the Safety and Tolerability of BID and QD Administration of XXXX in Patients with Mild to Moderate Dementia of the Alzheimer's Type. (3811x1)

7. A Phase III Study of the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203077PRN)

8. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety and Efficacy of XXXX in Patients with Restless Legs Syndrome. (203812PRN)

9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00012)

10. A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXXX in Subjects with Mild Cognitive Impairment. (202493)

11. A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of XXXX at Dosages up to 16mg/day in Adults with Generalized Anxiety Disorder. (202976)

12. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome. (203233)

13. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy. (203231)

14. A 12-Month, Open-Label, Flexible-Dosage (100-2500 mg/day) Extension Study of the Safety and Efficacy of XXXX in the Treatment of Patients with Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. (203903)

15. An Analysis of Mortality in Subjects who Participated in Three Studies of XXXX in Mild Cognitive Impairment. (00006)

16. A Study To Define the Non-Restorative Sleep Population. (00010)

17. A 6-Month Safety Follow-up Study to Select Patients Previously Enrolled and Randomized to XXXX in Studies XXXX, XXXX, or XXXX. (00028)

18. Evaluation of the Long-Term Efficacy and Safety of XXXX 12.5 mg Compared to Placebo, When Both are Administered Over a Long-Term Period "as needed", in Patients with Chronic Primary Insomnia. (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Mulicenter, Phase IIIb Clinical Study). (00007)

19. A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (00025)

20. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once Daily XXXX in Patients with Restless Legs Syndrome. (00036)

21. A Double-Blind, Placebo-Controlled Study of XXXX for the Treatment of Mild-To-Moderate Alzheimer's Disease. (00065)

22. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XXXX in Patients with Generalized Anxiety Disorder. (00054)

23. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00046)

24. A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study In Patients with Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered XXXX. (00063)

25. The Efficacy of XXXX 3 mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder. (00057)

26. A 12 Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of XXXX (Extended Release) in Patients with Restless Legs Syndrome. (00059)

27. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Primary Insomnia Patients with Sleep Maintenance Difficulties. (00047)

28. Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (00023)

29. A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicenter, Proof of Concept Trial of XXXX in Subjects with Nonrestorative Sleep. (00095)

30. Efficacy and Safety of XXXX 5mg/Day on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. (00103)

31. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of a Single Oral Dose of XXXX

(20, 50, and 100 mg) and Matching Placebo in Healthy Male and Female Subjects with Induced Transient Insomnia. (00107)

32. A Randomized, Double-Blind Comparison of 5 mg of XXXX, 15 mg of XXXX, and Placebo in the Treatment of Patients with Primary Insomnia. (00076)

33. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Effects of the XXXX in Patients with Insomnia. (00077)

34. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effects of XXXX (2.5, 10 and 30 mg) on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Nonelderly Subjects with Primary Insomnia. (00088)

35. A 28-Week Open-Label Extension Study Evaluating the Safety and Tolerability of XXXX (E2020) in Subjects with Mild Cognitive Impairment. (00105)

36. An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00093)

37. Open-Label Study of the Effect of Daily Treatment with XXXX in Subjects with Dementia of the Alzheimer's Type. (00139)

38. An 8-Week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy, Safety and Tolerability of XXXX 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-Week, Open-Label Extension (CAGO178A2302E). (00125)

39. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Restless Legs Syndrome. (00056)

40. An Open-Label, 52-Week Extension Study Assessing XXXX Safety and Efficacy in Patients with Restless Legs Syndrome. (00114)

41. A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XXXX in Patients with Restless Legs Syndrome. (00141)

42. Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (00128)

43. A Multi-Center, Double-Blind, Parallel-Group, Fixed-Dose, 4-Arm, Placebo and XXXX Controlled 8-Week Efficacy Study of 2 Oral Doses of XXXX (175 mg or 350 mg, bid) in Adult Outpatients with Major Depressive Disorder. (00022)

44. A 54-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of XXXX (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE ε4-Stratified Subjects with Mild to Moderate Alzheimer's Disease (REFLECT-3). (00123)

45. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of XXXX on Cognitive Functions in the Elderly. (00058 & 00228)

46. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluated the Efficacy and Safety of XXXX in Migraine Prophylaxis. (00082)

47. A 52-Week, Open-Label Study to Assess the Long-Term Safety of XXXX Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). (00075)

48. An Open-Label Extension of the Phase III Study CL-758007 with XXXX in Patients with Alzheimer's Disease. (00107)

49. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Demonstrate the Subjective Treatment Effects of XXXX on Sleep Using a Post Sleep Questionnaire-Interactive Voice Response System (PSQ-IVRS) in an "At-Home Setting" in an Adult Population with Chronic Insomnia. (00145)

50. Effect of XXXX in Slowing the Progression of Alzheimer's Disease. (00134)

51. A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of XXXX 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects. (00090)

52. A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of XXXX After 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment. (00163)

53. Efficacy and Safety of 2 mg/day XXXX on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study. (00192)

54. A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of XXXX Alone and in Combination with Donepezil in Subjects with Mild Alzheimer's Disease. (00144)

55. A 52-Week Open-Label Extension Study of the Long-Term Safety and Efficacy of XXXX Extended-Release (RSGXR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects with Mild-To-Moderate Alzheimer's Disease (AVA102675, REFLECT-4) (00220)

56. XXXX Dose-Ranging Trial: A Randomized, Double-Blind, Placebo-Controlled, 5-Way Crossover, Multicenter Polysomnography Trial of XXXX in Adults with Primary Insomnia. (00284)

57. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate The Efficacy and Safety of XXXX (20 MG/Day and 50 MG/Day) in the Treatment of Primary Insomnia. (00273)

58. A Randomized, Double-Blind, Active-and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XXXX-Treated Patients with Restless Legs Syndrome. (00227)

59. A Six-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial with XXXX in Patients With Chronic Primary Insomnia. (00118)

60. Fifty-Two Weeks, Open-Label Extension Trial To Evaluate Safety and Efficacy of XXXX in Outpatients with Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002. (00217)

61. A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of XXXX to Advance the Timing of Sleep in Individuals with Delayed Sleep Phase Syndrome (DSPS). (00198)

62. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of XXXX in Adult Migraineurs for a Single Migraine Followed by Open-Label Extensions to 26/52 Weeks. (00219)

63. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of XXXX Tablets Twice Daily in Adults with Mild to Moderate Alzheimer's Disease. (00214)

64. A Double-Blind, Randomized, Placebo-Controlled Study Examining, the Safety, Efficacy, and Tolerability of XXXX in Subjects with Major Depressive Disorder (Including Atypical and Melancholic Features). (00230)

65. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy and Safety of XXXX For The Treatment of Generalized Anxiety Disorder. (00275)

66. A Randomized, Long-Term Safety Study of XXXX in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 MG or 3.0 MG of XXXX. (00226)

67. A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of XXXX in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep. (00324)

68. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX at a Target Dosage of 200 MG/Day as Treatment for Adults with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome with Comorbid Major Depressive Disorder or Dysthymic Disorder. (00323)

69. Effect of y-Secretase Inhibition on the Progression of Alzheimer's Disease: XXXX Versus Placebo. (00294)

70. XXXX Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of XXXX in Adults with Non-Restorative Sleep. (00321)

71. A Phase 2a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (00318)

72. A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of Eighteen Months of Treatment with XXXX (XXXX) in Participants with Mild-To-Moderate Alzheimer's Disease. (00355)

73. A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (XXXX) or Placebo in Patients with Mild to Moderate Probable Alzheimer's Disease. (00343)

74. A 52 Week Open Label Safety Study of XXXX in Subjects with Generalized Anxiety Disorder. (00305)

75. A Polysomnography Study of XXXX (XXXX) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance. (00338)

76. Efficacy and Safety of XXXX 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: A 6-Week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography Study. (00350)

77. A Phase 2 Study of XXXX Compared with Placebo For the Treatment of Alcohol Dependence. (00347)

78. A Phase 3 Multicenter, Randomized, Placebo-Controlled, Twelve-Month Safety and Efficacy Study Evaluating XXXX in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil. (00404)

79. A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of XXXX in the Treatment of Alzheimer's Disease. (00382)

80. Randomized, Double-Blind, 12-Month Study of XXXX in Subjects with Restless Legs Syndrome. (00418)

81. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease. (00341)

82. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXXX in the Treatment of Patients with Prodromal Alzheimer's Disease. (00412)

83. A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of XXXX in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®). (00403)

84. An Open Label Study of the Safety and Tolerability of XXXX in Subjects with Alzheimer's Disease. (00446)

85. A Randomized, Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of the Effects of XXXX (200 mg/day) Treatment on Prefrontal Cortical Activation in Patients with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome. (00407)

86. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XXXX (50, 150 and 250 mg/day) as Treatment for Patients with Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury. (00397)

87. A Phase 2 Multicenter, Double Blind, Placebo Controlled, Parallel Group Study of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00440)

88. A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of XXXX (150 and 250mg/Day) as Treatment for Patients with Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury. (00506)

89. Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two XXXX Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC). (00516)

90. A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study of XXXX and XXXX in Adults with Restless Legs Syndrome. (00457)

91. Effect of Passive Immunization on the Progression of Alzheimer's Disease: XXXX (XXXX) Versus Placebo. (00503)

92. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long-Term Safety Study of XXXX in Patients with Primary Insomnia. (00448)

93. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of XXXX in Patients with Primary Insomnia – Study A. (00514)

94. An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating XXXX (XXXX) in Patients with Alzheimer's Disease. (00529)

95. A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of XXXX for the Acute Treatment of Migraine in Children and Adolescents. (00502)

96. A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of XXXX in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura. (00469)

97. Randomized, Double-Blind, 12-Week Study of XXXX in Subjects with Restless Legs Syndrome. (00515)

98. A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of XXXX Administered Once Daily to Subjects with an Excessive Daytime Sleepiness Disorder. (00541)

99. Continued Efficacy and Safety Monitoring of XXXX, an Anti-Amyloid β Antibody in Patients with Alzheimer's Disease. (00565)

100. A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00582)

101. A 4-Week, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Investigate the Safety and Efficacy of XXXX as Monotherapy in Patients with Treatment-Resistant Major Depression. (00585)

102. A Phase 2, Multicenter, Open-Label Study to Assess the Safety and Tolerability of Oral XXXX as Adjunctive Therapy in Adult Patients with Major Depressive Disorder. (00416)

103. A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety of XXXX in Subjects with Spasticity Due to Multiple Sclerosis. (00595)

104. An Open Label, 26-Week Study Assessing XXXX Safety and Efficacy in Subjects with Spasticity Associated with Multiple Sclerosis. (00614)

105. A Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed XXXX in Patients with Treatment Resistant Major Depression. (00571)

106. A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of XXXX in Subjects with Alzheimer's Disease on Donepezil. (00618)

107. A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of XXXX and XXXX Adjuvant in Subjects with Mild to Moderate Alzheimer's Disease. (00591)

108. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (00579)

109. A Multicenter, Double-Blind, 58-Week Rollover Study to Assess the Safety and Tolerability of XXXX in Patients with Treatment Resistant Major Depression. (00583)

110. A Study to Evaluate the Effects of XXXX in Patients with Chronic Obstructive Pulmonary Disease. (00619)

111. A Double-Blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of XXXX in Insomnia Patients Aged 18-80. (00635)

112. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Effectiveness of XXXX (Human), 10% Solution (XXXX, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease (AD). (00626)

113. A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of XXXX and Placebo in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study. (00658)

114. Effect of XXXX in Obese Subjects with Moderate or Severe Obstructive Sleep Apnoea A 32-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center and Multinational Trial. (00696)

115. A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Prodromal or Mild Alzheimer's Disease. (00700)

116. A Phase 2, Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of XXXX (XXXX/XXXX) for the Treatment of Symptoms of Agitation in Patients with Alzheimer's Disease. (00697)

117. A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients with Mild to Moderate Alzheimer's Disease. (00729)

118. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of XXXX in Subjects with Mild Alzheimer's Disease. (00722)

119. A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study of the Safety and Efficacy of XXXX in the Treatment of Excessive Daytime Sleepiness in Subjects with Narcolepsy. (00733)

120. A 26-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of Daily Administration of XXXX in Participants with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26-Week Open-Label Extension. (00731)

121. Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: XXXX (XXXX) Versus Placebo (00743)